Summary by Futu AI
On January 4, 2024, Aditxt, Inc., a biotech company focused on health innovations, completed a strategic acquisition of MDNA Life Sciences Inc.'s early cancer detection platform through its subsidiary Pearsanta, Inc. The acquisition, valued at approximately $25 million, includes the pioneering MitomicTM technology for early disease detection using mitochondrial DNA. The transaction was initially announced on December 17, 2023, and includes 50,000 shares of Aditxt common stock, warrants for an additional 50,000 shares, 5,000 shares of Pearsanta preferred stock, and up to $3.2 million under a transition services agreement. This acquisition aims to expand Pearsanta's diagnostic capabilities in women's and men's health, including endometriosis and prostate cancer. Additionally, Aditxt has amended its merger agreement with Evofem Biosciences, Inc., extending the filing date for the joint proxy statement to February 14, 2024. The acquisition and merger are part of Aditxt's broader strategy to deploy innovative health solutions and expand its market opportunities.
